MKI67 and breast cancer: Owing to its molecular heterogeneity, BC is differentiated into four subtypes based on the presence or absence of the following biomarkers: hormone receptors (HRs), human epidermal receptor 2 (HER2), and Ki-67 (cell proliferation marker).